This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Connell, J. M. Articles by Lever, A. F. Search for Related Content PubMed PubMed Citation Articles by Connell, J. M. Articles by Lever, A. F.

Hypertension, Vol 8, 669-676, Copyright © 1986 by American Heart Association

ARTICLES

Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia?

JM Connell, CJ Kenyon, JE Corrie, R Fraser, R Watt and AF Lever

Dexamethasone-suppressible hyperaldosteronism is a rare familial syndrome in which hypokalemia, suppression of plasma renin concentration, and elevated aldosterone secretion are corrected by treatment with glucocorticoids. Regulation of adrenocortical function and body electrolytes was studied in two affected brothers. Both were hypertensive (210/128 and 160/106 mm Hg) with hypokalemia (3.3 and 3.5 mM) and low plasma renin concentrations. Aldosterone was elevated intermittently with levels as high as 45 ng/dl (normal range, 4-16 ng/dl). Cortisol concentrations were normal but were correlated with aldosterone levels (r = 0.9 and 0.7). Concentrations of 11- deoxycorticosterone (19 and 21 ng/dl; normal range, 4-16 ng/dl) and 18- hydroxycortisol (1000 and 950 ng/dl; normal range, 34-150 ng/dl) were elevated, and diurnal changes in both were the same as those seen with aldosterone. Infusion of adrenocorticotropic hormone (ACTH) caused exaggerated increases of aldosterone, 11-deoxycorticosterone, and 18- hydroxycortisol; cortisol response was normal. A 4-week trial of dexamethasone normalized blood pressure and caused a natriuresis, a fall in aldosterone, and a rise in plasma renin. Administration of ACTH after dexamethasone treatment again caused exaggerated increases of aldosterone. Aldosterone did not respond to angiotensin II before dexamethasone therapy (r = 0.01), but it showed a normal response after therapy (r = 0.8, p less than 0.01). Neither administration of dopamine (1 microgram/kg/min) nor long-term therapy with bromocriptine (2.5 mg t.i.d. for 4 weeks) affected aldosterone biosynthesis. Thus, loss of dopaminergic inhibition of mineralocorticoid biosynthesis does not account for hyperaldosteronism in this condition.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. Stowasser, R. D Gordon, J. C Rutherford, N. Z Nikwan, N. Daunt, and G. J Slater Review: Diagnosis and management of primary aldosteronism Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 156 - 169. [PDF]

				M. Stowasser, A. W. Bachmann, P. R. Huggard, T. R. Rossetti, and R. D. Gordon Treatment of Familial Hyperaldosteronism Type I: Only Partial Suppression of Adrenocorticotropin Required to Correct Hypertension J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3313 - 3318. [Abstract] [Full Text]

				M. Stowasser, A. W. Bachmann, P. R. Huggard, T. R. Rossetti, and R. D. Gordon Severity of Hypertension in Familial Hyperaldosteronism Type I: Relationship to Gender and Degree of Biochemical Disturbance J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2160 - 2166. [Abstract] [Full Text]

				W. R. Litchfield, M. I. New, C. Coolidge, R. P. Lifton, and R. G. Dluhy Evaluation of the Dexamethasone Suppression Test for the Diagnosis of Glucocorticoid-Remediable Aldosteronism J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3570 - 3573. [Abstract] [Full Text] [PDF]

				M. Stowasser, M. G. Gartside, W. L. Taylor, T. J. Tunny, and R. D. Gordon In Familial Hyperaldosteronism Type I, Hybrid Gene-Induced Aldosterone Production Dominates That Induced by Wild-Type Genes J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3670 - 3676. [Abstract] [Full Text] [PDF]